Therapeutic Perspectives for the Clinical Application of Umbilical Cord Hematopoietic and Mesenchymal Stem Cells: Overcoming Complications Arising After Allogeneic Hematopoietic Stem Cell Transplantation.
Hematologic diseases
Hematopoietic stem cell
Mesenchymal stem cell
Stem cell transplantation
Umbilical cord
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
pubmed:
23
8
2022
medline:
25
3
2023
entrez:
22
8
2022
Statut:
ppublish
Résumé
This review focuses on the therapeutic features of umbilical cord blood (UCB) cells as a source for allogeneic hematopoietic stem cell transplantation (aHSCT) in adult and child populations to treat malignant and nonmalignant hematologic diseases, genetic disorders, or pathologies of the immune system, when standard treatment (e.g., chemotherapy) is not effective or clinically contraindicated. In this article, we summarize the immunological properties and the advantages and disadvantages of using UCB stem cells and discuss a variety of treatment outcomes using different sources of stem cells from different donors both in adults and pediatric population. We also highlight the critical properties (total nucleated cell dose depending on HLA compatibility) of UCB cells that reach better survival rates, reveal the advantages of double versus single cord blood unit transplantation, and present recommendations from the most recent studies. Moreover, we summarize the mechanism of action and potential benefit of mesenchymal umbilical cord cells and indicate the most common posttransplantation complications.
Identifiants
pubmed: 35995905
doi: 10.1007/5584_2022_726
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-126Informations de copyright
© 2022. Springer Nature Switzerland AG.
Références
Abdulrazzak H, Moschidou D, Jones G, Guillot PV (2010) Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface 7(Suppl 6):S689–S706. https://doi.org/10.1098/rsif.2010.0347.focus
doi: 10.1098/rsif.2010.0347.focus
pubmed: 20739312
pmcid: 2988276
Admiraal R et al (2016a) Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis. Bone Marrow Transplant 51:1376–1378
pubmed: 27159172
doi: 10.1038/bmt.2016.116
Admiraal R et al (2016b) Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 128:2734–2741
pubmed: 27702800
doi: 10.1182/blood-2016-06-721936
Algeri M, Gaspari S, Locatelli F (2020) Cord blood transplantation for acute leukemia. Expert Opin Biol Ther 20:1223–1236
pubmed: 32529854
doi: 10.1080/14712598.2020.1782380
Anand S et al (2017) Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant 23:1151–1157
pubmed: 28392378
pmcid: 5846194
doi: 10.1016/j.bbmt.2017.04.001
Anasetti C et al (2012) Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367:1487–1496
pubmed: 23075175
doi: 10.1056/NEJMoa1203517
Arno A et al (2011) Stem cell therapy: a new treatment for burns? Pharmaceuticals (Basel) 4:1355–1380
pubmed: 27721328
pmcid: 4060129
doi: 10.3390/ph4101355
Awaya N, Rupert K, Bryant E, Torok-Storb B (2002) Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 30:937–942
pubmed: 12160845
doi: 10.1016/S0301-472X(02)00821-4
Ball LM et al (2007) Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110:2764–2767
pubmed: 17638847
doi: 10.1182/blood-2007-04-087056
Ballen KK, Gluckman E, Broxmeyer HE (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122:491–498
pubmed: 23673863
pmcid: 3952633
doi: 10.1182/blood-2013-02-453175
Balligand L et al (2019) Single-unit versus double-unit umbilical cord blood transplantation in children and young adults with residual leukemic disease. Biol Blood Marrow Transplant 25:734–742
pubmed: 30385256
doi: 10.1016/j.bbmt.2018.10.016
Barker JN et al (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97:2957–2961
pubmed: 11342417
doi: 10.1182/blood.V97.10.2957
Barker JN et al (2010) Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 16:1541–1548
pubmed: 20800103
pmcid: 3685152
doi: 10.1016/j.bbmt.2010.08.011
Baron F et al (2017) Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol 10(1):128. Full Text. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0497-9
Beksac M (2016) Is there any reason to prefer cord blood instead of adult donors for hematopoietic stem cell transplants? Front Med 2:95
doi: 10.3389/fmed.2015.00095
Berglund S, Magalhaes I, Gaballa A, Vanherberghen B, Uhlin M (2017) Advances in umbilical cord blood cell therapy: the present and the future. Expert Opin Biol Ther 17:691–699
pubmed: 28379044
doi: 10.1080/14712598.2017.1316713
Beziat V et al (2009) Fully functional NK cells after unrelated cord blood transplantation. Leukemia 23:721–728
pubmed: 19151772
doi: 10.1038/leu.2008.343
Brunstein CG et al (2009) Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 43:935–940
pubmed: 19139736
pmcid: 5157830
doi: 10.1038/bmt.2008.417
Brunstein CG et al (2010) Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699
pubmed: 20686119
pmcid: 2996124
doi: 10.1182/blood-2010-05-285304
Campagnoli C et al (2001) Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98:2396–2402
pubmed: 11588036
doi: 10.1182/blood.V98.8.2396
Chao Y-H et al (2011) Cotransplantation of umbilical cord MSCs to enhance engraftment of hematopoietic stem cells in patients with severe aplastic anemia. Bone Marrow Transplant 46:1391–1392
pubmed: 21113191
doi: 10.1038/bmt.2010.305
Cheng K et al (2013) Bone-derived mesenchymal stromal cells from HIV transgenic mice exhibit altered proliferation, differentiation capacity and paracrine functions along with impaired therapeutic potential in kidney injury. Exp Cell Res 319:2266–2274
pubmed: 23806280
pmcid: 3779877
doi: 10.1016/j.yexcr.2013.06.008
Cohen Y, Nagler A (2004) Umbilical cord blood transplantation – how, when and for whom? Blood Rev 18:167–179
pubmed: 15183901
doi: 10.1016/S0268-960X(03)00064-X
Cohen S et al (2020) Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol 7:e134–e145
pubmed: 31704264
doi: 10.1016/S2352-3026(19)30202-9
Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826
pubmed: 16641398
doi: 10.1056/NEJMra052638
Cutler C et al (2013) Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122:3074–3081
pubmed: 23996087
pmcid: 3811179
doi: 10.1182/blood-2013-05-503177
Dahlberg A, Milano F (2017) Cord blood transplantation: rewind to fast forward. Bone Marrow Transplant 52:799–802
pubmed: 27991893
doi: 10.1038/bmt.2016.336
Dalle JH et al (2004) Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant 33:605–611
pubmed: 14743192
doi: 10.1038/sj.bmt.1704433
Dave H et al (2017) Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood. Mol Ther Methods Clin Dev 5:13–21
pubmed: 28480300
pmcid: 5415312
doi: 10.1016/j.omtm.2017.02.001
de Koning C, Admiraal R, Nierkens S, Boelens JJ (2017) Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig 4:38
pubmed: 28607912
pmcid: 5460145
doi: 10.21037/sci.2017.05.02
de Lima M et al (2008) Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 41:771–778
pubmed: 18209724
pmcid: 4086223
doi: 10.1038/sj.bmt.1705979
de Lima M et al (2012) Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367:2305–2315
pubmed: 23234514
pmcid: 3805360
doi: 10.1056/NEJMoa1207285
Deans RJ, Moseley AB (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28:875–884
pubmed: 10989188
doi: 10.1016/S0301-472X(00)00482-3
Delaney M, Ballen KK (2010) The role of HLA in umbilical cord blood transplantation. Best Pract Res Clin Haematol. PMID: 20837329 Review. https://ur.booksc.eu/book/16595378/b31541
Delaney C et al (2010) Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16:232–236
pubmed: 20081862
pmcid: 2819359
doi: 10.1038/nm.2080
Delayed umbilical cord clamping after birth (2020) https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/articles/2020/12/delayed-umbilical-cord-clamping-after-birth
Dessels C, Alessandrini M, Pepper MS (2018) Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape. Stem Cells Transl Med 7:643–650
pubmed: 29777574
pmcid: 6127225
doi: 10.1002/sctm.17-0244
Deuse T et al (2011) Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 20:655–667
pubmed: 21054940
doi: 10.3727/096368910X536473
Divya MS et al (2012) Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. Stem Cell Res Ther 3:57
pubmed: 23253356
pmcid: 3580487
doi: 10.1186/scrt148
Dominici M et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
pubmed: 16923606
doi: 10.1080/14653240600855905
Eapen M et al (2007) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369:1947–1954
pubmed: 17560447
doi: 10.1016/S0140-6736(07)60915-5
Eapen M et al (2011) Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 12:1214–1221
pubmed: 21982422
pmcid: 3245836
doi: 10.1016/S1470-2045(11)70260-1
Eapen M et al (2017) Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol 4:e325–e333
pubmed: 28623181
pmcid: 5699478
doi: 10.1016/S2352-3026(17)30104-7
Edinger M et al (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150
pubmed: 12925844
doi: 10.1038/nm915
Expansion of human cord blood hematopoietic stem cells for transplantation (2010) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962561/
Farag SS et al (2013) In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 22:1007–1015
pubmed: 23270493
doi: 10.1089/scd.2012.0636
Frassoni F et al (2010) The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. Best Pract Res Clin Haematol 23:237–244
pubmed: 20837336
doi: 10.1016/j.beha.2010.06.003
Gabelli M, Veys P, Chiesa R (2020) Current status of umbilical cord blood transplantation in children. Br J Haematol 190:650–683
pubmed: 31410846
doi: 10.1111/bjh.16107
Galderisi U, Peluso G, Di Bernardo G (2021) Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Rev Rep 1–14. https://doi.org/10.1007/s12015-021-10231-w
Galipeau J, Sensébé L (2018) Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22:824–833
pubmed: 29859173
pmcid: 6434696
doi: 10.1016/j.stem.2018.05.004
Galleu A et al (2017) Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med 9:eaam7828
pubmed: 29141887
doi: 10.1126/scitranslmed.aam7828
Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M (2015) Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev Rep 11:280–287
pubmed: 25592610
doi: 10.1007/s12015-014-9583-3
Gluckman E, Rocha V (2009) Cord blood transplantation: state of the art. Haematologica 94:451–454
pubmed: 19336748
pmcid: 2663606
doi: 10.3324/haematol.2009.005694
Gluckman E et al (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321:1174–1178
pubmed: 2571931
doi: 10.1056/NEJM198910263211707
Gluckman E et al (2004) Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 32:397–407
pubmed: 15050751
doi: 10.1016/j.exphem.2004.01.002
Gragert L et al (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371:339–348
pubmed: 25054717
pmcid: 5965695
doi: 10.1056/NEJMsa1311707
Gupta AO, Wagner JE (2020) Umbilical cord blood transplants: current status and evolving therapies. Front Pediatr 8:570282
pubmed: 33123504
pmcid: 7567024
doi: 10.3389/fped.2020.570282
Hariri R (2004) Use of umbilical cord blood to treat individuals having a disease, disorder or condition. https://patents.google.com/patent/US20040219136A1/en#patentCitations
Harrell CR et al (2019) Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of glaucoma. Stem Cells Int 2019:e7869130
doi: 10.1155/2019/7869130
Harrell CR, Popovska Jovicic B, Djonov V, Volarevic V (2021) Molecular mechanisms responsible for mesenchymal stem cell-based treatment of viral diseases. Pathogens 10:409
pubmed: 33915728
pmcid: 8066286
doi: 10.3390/pathogens10040409
He X et al (2005) Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells. Stem Cells Dev 14:188–198
pubmed: 15910245
doi: 10.1089/scd.2005.14.188
Heinze A et al (2019) The synergistic use of IL-15 and IL-21 for the generation of NK cells from CD3/CD19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: perspective for optimized immunotherapy post haploidentical stem cell transplantation. Front Immunol 10:2816
pubmed: 31849984
pmcid: 6901699
doi: 10.3389/fimmu.2019.02816
Herr A-L et al (2010) Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 116:1849–1856
pubmed: 20538797
doi: 10.1182/blood-2010-02-271692
Hexner EO et al (2016) Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol 91:453–460
pubmed: 26858124
pmcid: 6145177
doi: 10.1002/ajh.24303
Horwitz ME et al (2014) Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 124:3121–3128
pubmed: 24911148
pmcid: 4071379
doi: 10.1172/JCI74556
Hough R et al (2016) Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol 172:360–370
pubmed: 26577457
doi: 10.1111/bjh.13802
Ito Y, Hasauda H, Kitajima T, Kiyono T (2006) Ex vivo expansion of human cord blood hematopoietic progenitor cells using glutaraldehyde-fixed human bone marrow stromal cells. J Biosci Bioeng 102:467–469
pubmed: 17189177
doi: 10.1263/jbb.102.467
Jacobson CA et al (2012) Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 18:565–574
pubmed: 21875503
doi: 10.1016/j.bbmt.2011.08.018
Jaroscak J et al (2003) Augmentation of umbilical cord blood (UCB) transplantation with ex vivo–expanded UCB cells: results of a phase 1 trial using the AastromReplicell system. Blood 101:5061–5067
pubmed: 12595310
doi: 10.1182/blood-2001-12-0290
Kanda J et al (2012) Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:1664–1676.e1
pubmed: 22698485
pmcid: 3472115
doi: 10.1016/j.bbmt.2012.06.005
Keating AK et al (2019) The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv 3:1118–1128
pubmed: 30952678
pmcid: 6457227
doi: 10.1182/bloodadvances.2018025908
Kelly K, Rasko JEJ (2021) Mesenchymal stromal cells for the treatment of graft versus host disease. Front Immunol 12:4457
doi: 10.3389/fimmu.2021.761616
Kim Y-J, Broxmeyer HE (2011) Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol 79:112–126
pubmed: 20727784
doi: 10.1016/j.critrevonc.2010.07.009
Koç ON et al (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18:307–316
pubmed: 10637244
doi: 10.1200/JCO.2000.18.2.307
Lazennec G, Jorgensen C (2008) Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 26:1387–1394
pubmed: 18388305
doi: 10.1634/stemcells.2007-1006
Le Blanc K et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441
pubmed: 15121408
doi: 10.1016/S0140-6736(04)16104-7
Leber A, Teles A, Zenclussen AC (2010) Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 63:445–459
pubmed: 20331584
doi: 10.1111/j.1600-0897.2010.00821.x
Li T, Xia M, Gao Y, Chen Y, Xu Y (2015) Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther 15:1293–1306
pubmed: 26067213
doi: 10.1517/14712598.2015.1051528
Li X et al (2016) Human umbilical cord blood-derived mesenchymal stem cells contribute to chondrogenesis in coculture with chondrocytes. Biomed Res Int 2016:e3827057
Li D, Li X, Liao L, Li N (2020) Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-a meta-analysis and systematic review. Am J Blood Res 10:1–10
pubmed: 32206440
pmcid: 7076284
Locatelli F (2009) Improving cord blood transplantation in children. Br J Haematol 147:217–226
pubmed: 19796271
doi: 10.1111/j.1365-2141.2009.07783.x
Locatelli F et al (2014) Comparison between related T-cell depleted HLA-haploidentical stem cell transplantation (TCD-Haplo) and umbilical cord blood transplantation (UCBT) in pediatric patients with acute leukemia, a Eurocord, PDWP-EBMT study. Blood 124:1215
doi: 10.1182/blood.V124.21.1215.1215
Lu L-L et al (2006) Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91:1017–1026
pubmed: 16870554
Malgieri A, Kantzari E, Patrizi MP, Gambardella S (2010) Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 3:248–269
pubmed: 21072260
pmcid: 2971538
Marino L et al (2019) Mesenchymal stem cells from the Wharton’s jelly of the human umbilical cord: biological properties and therapeutic potential. Int J Stem Cells 12:218–226
pubmed: 31022994
pmcid: 6657936
doi: 10.15283/ijsc18034
Matsuzuka T et al (2010) Human umbilical cord matrix–derived stem cells expressing interferon-β gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 70:28–36
pubmed: 20138387
doi: 10.1016/j.lungcan.2010.01.003
Mayani H (2010) Biological differences between neonatal and adult human hematopoietic stem/progenitor cells. Stem Cells Dev 19:285–298
pubmed: 19778207
doi: 10.1089/scd.2009.0327
Mayani H, Lansdorp PM (1998) Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16:153–165
pubmed: 9617891
doi: 10.1002/stem.160153
Mayani H, Wagner JE, Broxmeyer HE (2020) Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant 55:48–61
pubmed: 31089283
doi: 10.1038/s41409-019-0546-9
McKenna DH et al (2017) Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 19:250–262
pubmed: 27887864
doi: 10.1016/j.jcyt.2016.10.011
Mehta RS et al (2017) Ex vivo mesenchymal precursor cell-expanded cord blood transplantation after reduced-intensity conditioning regimens improves time to neutrophil recovery. Biol Blood Marrow Transplant 23:1359–1366
pubmed: 28506845
pmcid: 6453532
doi: 10.1016/j.bbmt.2017.05.002
Merindol N, Charrier E, Duval M, Soudeyns H (2011) Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol 90:49–60
pubmed: 21367975
doi: 10.1189/jlb.0111007
Michel G et al (2016) Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 127:3450–3457
pubmed: 27099151
doi: 10.1182/blood-2016-01-694349
Milano F et al (2016) Cord-blood transplantation in patients with minimal residual disease. N Engl J Med 375:944–953
pubmed: 27602666
pmcid: 5513721
doi: 10.1056/NEJMoa1602074
Molecule boosts numbers of stem cells in umbilical cord blood. Sci News (2014) https://www.sciencenews.org/article/molecule-boosts-numbers-stem-cells-umbilical-cord-blood
Nagamura-Inoue T, He H (2014) Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells 6:195–202
pubmed: 24772246
pmcid: 3999777
doi: 10.4252/wjsc.v6.i2.195
Nham T et al (2018) Ex vivo-expanded natural killer cells derived from long-term cryopreserved cord blood are cytotoxic against primary breast cancer cells. J Immunother 41:64–72
pubmed: 29189387
doi: 10.1097/CJI.0000000000000192
Oran B, Shpall E (2012) Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012:215–222
pubmed: 23233584
doi: 10.1182/asheducation.V2012.1.215.3798291
Passweg JR et al (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 51:786–792
pubmed: 26901709
pmcid: 4895175
doi: 10.1038/bmt.2016.20
Poloni A et al (2006) Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 20:329–335
pubmed: 16341047
doi: 10.1038/sj.leu.2404018
Popat U et al (2015) Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125:2885–2892
pubmed: 25778529
pmcid: 4424412
doi: 10.1182/blood-2015-01-607366
Preterm labour and birth (NICE guideline NG25) (2020) https://www.nice.org.uk/guidance/ng25/resources/preterm-labour-and-birth-pdf-1837333576645
Ramirez P et al (2012) Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant 47:799–803
pubmed: 21946383
doi: 10.1038/bmt.2011.184
Rocha V, Locatelli F (2008) Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 41:207–214
pubmed: 18084331
doi: 10.1038/sj.bmt.1705963
Rocha V et al (2000) Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342:1846–1854
pubmed: 10861319
doi: 10.1056/NEJM200006223422501
Rocha V et al (2001) Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97:2962–2971
pubmed: 11342418
doi: 10.1182/blood.V97.10.2962
Rocha V, Gluckman E, Eurocord and European Blood and Marrow Transplant Group (2006) Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant 12:34–41
pubmed: 16399582
doi: 10.1016/j.bbmt.2005.09.006
Rocha V, Gluckman E, Eurocord-Netcord Registry and European Blood and Marrow Transplant Group (2009) Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147:262–274
pubmed: 19796275
doi: 10.1111/j.1365-2141.2009.07883.x
Rollín R et al (2007) Human parvovirus B19, varicella zoster virus, and human herpesvirus-6 in mesenchymal stem cells of patients with osteoarthritis: analysis with quantitative real-time polymerase chain reaction. Osteoarthr Cartil 15:475–478
doi: 10.1016/j.joca.2006.11.007
Roura S, Pujal J, Gálvez-Montón C, Bayes-Genis A (2015) The role and potential of umbilical cord blood in an era of new therapies: a review. Stem Cell Res Ther 6:123
pubmed: 26133757
pmcid: 4489204
doi: 10.1186/s13287-015-0113-2
Rubinstein P et al (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565–1577
pubmed: 9828244
doi: 10.1056/NEJM199811263392201
Secco M et al (2008) Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells 26:146–150
pubmed: 17932423
doi: 10.1634/stemcells.2007-0381
Selmani Z et al (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26:212–222
pubmed: 17932417
doi: 10.1634/stemcells.2007-0554
Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54:1418–1437
pubmed: 24898458
doi: 10.1111/trf.12421
Sleem A, Saleh F (2020) Mesenchymal stem cells in the fight against viruses: face to face with the invisible enemy. Curr Res Transl Med 68:105–110
pubmed: 32616467
pmcid: 7252154
doi: 10.1016/j.retram.2020.04.003
Soland MA et al (2014) Perivascular stromal cells as a potential reservoir of human cytomegalovirus. Am J Transplant 14:820–830
pubmed: 24592822
pmcid: 4046334
doi: 10.1111/ajt.12642
Spees JL, Lee RH, Gregory CA (2016) Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 7:125
pubmed: 27581859
pmcid: 5007684
doi: 10.1186/s13287-016-0363-7
Stavropoulos-Giokas C, Dinou A, Papassavas A (2012) The role of HLA in cord blood transplantation. Bone Marrow Res 2012:e485160
doi: 10.1155/2012/485160
Stenderup K, Justesen J, Clausen C, Kassem M (2003) Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33:919–926
pubmed: 14678851
doi: 10.1016/j.bone.2003.07.005
Stiff PJ et al (2018) Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biol Blood Marrow Transplant 24:1463–1470
pubmed: 29477778
pmcid: 6045964
doi: 10.1016/j.bbmt.2018.02.012
Sun JM et al (2017) Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, Placebo-Controlled Trial. Stem Cells Transl Med 6:2071–2078
pubmed: 29080265
pmcid: 5702515
doi: 10.1002/sctm.17-0102
Sun JM et al (2021) Umbilical cord blood and cord tissue mesenchymal stromal cells in children with cerebral palsy. Cytotherapy 10:S106–S106
doi: 10.1016/S1465324921004394
Sundin M et al (2006) Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 37:1051–1059
pubmed: 16604097
doi: 10.1038/sj.bmt.1705368
Szabolcs P, Niedzwiecki D (2007) Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 9:111–122
pubmed: 17453963
pmcid: 2203410
doi: 10.1080/14653240701231014
Terai S et al (2006) Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24:2292–2298
pubmed: 16778155
doi: 10.1634/stemcells.2005-0542
Terness P et al (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196:447–457
pubmed: 12186837
pmcid: 2196057
doi: 10.1084/jem.20020052
Thanunchai M, Hongeng S, Thitithanyanont A (2015) Mesenchymal stromal cells and viral infection. Stem Cells Int 2015:e860950
doi: 10.1155/2015/860950
Tsuda S, Nakashima A, Shima T, Saito S (2019) New paradigm in the role of regulatory T cells during pregnancy. Front Immunol 10:573. https://doi.org/10.3389/fimmu.2019.00573
doi: 10.3389/fimmu.2019.00573
pubmed: 30972068
pmcid: 6443934
Tsukamoto A, Baum CM, Aihara Y, Weissman I (1997) Identification and isolation of human hematopoietic stem cells. https://patents.google.com/patent/US5643741A/en
Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation. https://www.hindawi.com/journals/bmri/2012/759503/
US7332334B2 – hematopoietic stem cells treated by in vitro fucosylation and methods of use – Google Patents. https://patents.google.com/patent/US7332334B2/en
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa1910607
Verneris MR, Miller JS (2009) The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol 147:185–191
pubmed: 19796267
pmcid: 2770803
doi: 10.1111/j.1365-2141.2009.07768.x
Villaron EM et al (2004) Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica 89:1421–1427
pubmed: 15590390
Volarevic V et al (2017) Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential. Biofactors 43:633–644
pubmed: 28718997
doi: 10.1002/biof.1374
Wagner W et al (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33:1402–1416
pubmed: 16263424
doi: 10.1016/j.exphem.2005.07.003
Wagner JE et al (2014) One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med 371:1685–1694
pubmed: 25354103
pmcid: 4257059
doi: 10.1056/NEJMoa1405584
Wagner JE et al (2016) Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 18:144–155
pubmed: 26669897
doi: 10.1016/j.stem.2015.10.004
Wang Y et al (2007) High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 4:377–382
pubmed: 17976318
Wang L et al (2019) Single-versus double-unit umbilical cord blood transplantation for hematologic diseases: a systematic review. Transfus Med Rev 33:51–60
pubmed: 30482420
doi: 10.1016/j.tmrv.2018.11.001
Weiss ARR, Dahlke MH (2019) Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 10:1191
pubmed: 31214172
pmcid: 6557979
doi: 10.3389/fimmu.2019.01191
Westin JR et al (2011) Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011:601953
pubmed: 22110505
pmcid: 3216266
doi: 10.1155/2011/601953
Wu K-H et al (2011) Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation 91:1412–1416
pubmed: 21494176
doi: 10.1097/TP.0b013e31821aba18
Zhang Z-Y et al (2009) Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells 27:126–137
pubmed: 18832592
doi: 10.1634/stemcells.2008-0456
Zhang X et al (2013) Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy. Front Immunol 4:101
pubmed: 23641243
pmcid: 3640206
Zhou C et al (2011) Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol 272:33–38
pubmed: 22004796
pmcid: 3235326
doi: 10.1016/j.cellimm.2011.09.010
Zuk PA et al (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279–4295
pubmed: 12475952
pmcid: 138633
doi: 10.1091/mbc.e02-02-0105